Klompmaker I J, Haagsma E B, Gouw A S, Verwer R, Slooff M J
University Hospital, Liver Transplantation Group, Groningen, The Netherlands.
Transplantation. 1989 Nov;48(5):814-8. doi: 10.1097/00007890-198911000-00018.
Improvement of graft survival after orthotopic liver transplantation is often attributed to cyclosporine. In order to assess the effects on liver function and histology, we compared the results of conventional immunosuppression (azathioprine/prednisolone = group I) and a triple drug regimen, which included CsA (group II) during the first year after transplantation. Group I consisted of 33 patients; group II of 18 patients. Significant differences are present in favor of the CsA regimen with regard to transaminases and cholestatic parameters. Liver synthesis function was slightly better, though already very good under conventional immunosuppression. One week after transplantation, normal histology was not observed in group I, while 90% of the patients showed acute rejection. In group II, 53% of the patients showed normal histology; only 40% of the patients in group II showed acute rejection (P less than 0.0002). One year after transplantation, liver histology was normal in 57% of the conventionally treated patients and in 90% of the CsA-treated patients. Also, less rejection occurred in group II during the first year after transplantation. One-year graft survival was 67% in group I and in group II 75%, which is not statistically different. Creatinine clearance did not differ in both groups. However compared with pretransplantation creatinine clearances, kidney function in the CsA-treated patients decreased with approximately 20 ml/min. These results show that liver synthesis and liver function are better under the CsA-containing triple-drug-maintenance regimen, which is supported by the far better liver histology. Kidney function is reduced, even under low dose CsA treatment.
原位肝移植后移植物存活率的提高通常归因于环孢素。为了评估其对肝功能和组织学的影响,我们比较了传统免疫抑制方案(硫唑嘌呤/泼尼松龙=第一组)和三联药物方案(移植后第一年包括环孢素,第二组)的结果。第一组有33例患者;第二组有18例患者。在转氨酶和胆汁淤积参数方面,支持环孢素方案存在显著差异。肝合成功能稍好,尽管在传统免疫抑制下已经非常好。移植后一周,第一组未观察到正常组织学,而90%的患者出现急性排斥反应。在第二组中,53%的患者组织学正常;第二组中只有40%的患者出现急性排斥反应(P小于0.0002)。移植后一年,57%接受传统治疗的患者和90%接受环孢素治疗的患者肝脏组织学正常。此外,移植后第一年第二组发生的排斥反应较少。第一组的一年移植物存活率为67%,第二组为75%,无统计学差异。两组的肌酐清除率无差异。然而,与移植前的肌酐清除率相比,接受环孢素治疗的患者肾功能下降了约20 ml/min。这些结果表明,在含环孢素的三联药物维持方案下,肝脏合成和肝功能更好,这得到了更好的肝脏组织学的支持。即使在低剂量环孢素治疗下,肾功能也会降低。